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Angiotensin-converting enzyme (ACE) inhibitors are a significant group of drugs that 
are primarily used in the treatment of hypertension and congestive heart failure. Even 
though they belong to the same group of drugs and have similar efficacy, ACE inhibitors 
exhibit different pharmacological characteristics. The lipophilicity is one of the most 
important properties of biologically active substances. It influences their absorption, 
distribution, tissue penetration, action, elimination. In this paper, the elimination of ACE 
inhibitors by peritoneal dialisate in patients on peritoneal dialysis was investigated. The 
influence of ACE inhibitors' hydrophibicity in this way of elimination was discussed. Acta 
Medica Medianae 2011;50(2):12-17. 
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Angiotensin - converting enzyme (ACE) 
inhibitors represent significant group of drugs 
widely used in the treatment of hypertension, 
congestive heart failure and renal failure, 
especially in patients with diabetes mellitus and / 
or proteinuria. They were introduced in clinical 
practice three decades ago and today are the 
most commonly prescribed antihypertensive 
drugs (1).  
ACE inhibitors are complex organic molecules. 
Based on the differences in chemical structure, they 
can be classified into three groups: those with the 
sulfhydryl group (captopril), those with a carboxyl 
group (enalapril, cilazapril, ramipril, lisinopril and 
others) and those with the phosphoric group 
(fosinopril) (2).  
The ACE inhibitors are esterified prodrugs. 
Following administration, in vivo, they undergo 
hydrolysis into di-acid active metabolites, with 
exception of lisinopril, which is already in di-acid 
form, and captopril, which forms disulfide. In the 
biological materials, plasma, serum or urine, ACE 
inhibitors can be found as their metabolites just 
several hours after administration  (2,3).  
Active metabolites of ACE inhibitors demon-
strate their antihypertensive effect by modulation 
of the renin-angiotensin-aldosterone enzymatic 
system and selective dilation of efferent renal 
arterioles. In addition to antihypertensive, ACE 
inhibitors exhibit many other effects – anti-
proliferative, antiaterosclerotic, fibrinolytic (4). In 
hypertensive patients with renal failure, particularly 
of diabetic etiology, ACE inhibitors are used as 
drugs of choice because, in addition to antihyper-
tensive effects, they slow the progression of 
microalbuminuria and proteinuria (5-7). They are 
also often applied in patients with end-stage 
renal failure treated with renal replacement 
therapy - hemo or peritoneal dialysis. 
Pharmacological and pharmacodynamic 
properties of ACE inhibitors (absorption, distribution, 
activity, elimination) differ depending on their 
lipophilicity. The lipophilicity of drug molecules is 
defined by its distribution between the aqueous 
and non-aqueous phase and can be  expressed 
as the logarithm of n-octanol/water partition 
coefficient (log P). It plays an important role in 
drugs absorption, distribution, binding to plasma 
proteins and elimination. Lipophilic molecules 
show better absorption, penetration into tissues 
and have a higher degree of distribution compared 
to less lipophilic ones with similar properties. 
Also, the lipophilicity affects the duration of 
action of a drug, as well as efficiency of its 
elimination. Namely, weakly lipophilic drugs are 
eliminated by the urine, while the highly lipophilic 
ones can be eliminated by feces. Also, lipo-
philicity affects drugs elimination via the 
dialysate in renal patients on peritoneal dialysis. 
The very lipophilic drugs will be poorly eliminated 
by dialisate than the less lipophilic ones (8-14).  
Pharmacological properties (absorption, protein 
binding, distribution, activity, duration of action 
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and elimination), as well as their relationship with 
the lipophilicity of ACE inhibitors, were investigated 
in numerous studies by HPLC, thin layer 
chromatography, capillary electrophoresis, spectro-
photometry and spectrofluorimetry. ACE inhibitors 
were determined in pharmaceutical formulations 
and biological material, but there is little data on 
the elimination of ACE inhibitors by peritoneal 
dialysate (8-21).  
In our previous studies, we examined the 
lipophilicity of several ACE inhibitors using thin-
layer chromatography (22-24). The aim of this 
study is to monitor the elimination of ACE 
inhibitors by peritoneal dialysate as well as the 
influence of their lipophilicity on this way of 
elimination.  
 




In this paper, the elimination of two ACE 
inhibitors of different lipophilicity: cilazapril (log P 
= 1,04) and fosinopril (log P = 8,93) and their 
active metabolites cilazaprilat (log P = 0,46) and 
fosinoprilat (log P = 6,38) were investigated (22-
24). The structure of the investigated drugs are 
shown in Table 1. 
 
Peritoneal Dialisate Samples 
 
The dialysate samples were collected from 
16 hypertensive patients on peritoneal dialysis, 
12 h after oral administration of fosinopril 20 mg 
(8 patients) or cilazapril 10 mg (8 patients). All 
patients were on continuous treatment with 
fosinopril or cilazapril and no other antihipertensive 
drugs. Blank dialysate samples were obtained from 
several patients on peritoneal dialysis, but not 
treated with ACE inhibitors. 
 
 13
Clean – up procedure  
 
The investigated substances were extracted 
from prepared standard solution and dialysate 
samples obtained from patients, by SPE extraction 
on Bakerbond speTM Octadecyl (C18) columns, 
using the procedure established for urine samples 
by Prieto et al. (19).  
The extraction columns for cilazapril and 
cilazaprilat were activated by solution of methanol, 
water and borate buffer, pH=9. The examined 
samples (25 ml) with the added borate buffer were 
missed through the activated columns. The 
columns were rinsed with phosphate buffer and 
water, dried under vacuum and n-hexane solution. 
After rinsing and drying columns, the examined 
substances were eluted with methanol. The 
methanol solution was matched to dry and 
dissolved in a solution of mobile phase to volume 
of 200 µL.  
The extraction columns for fosinopril and 
fosinoprilat were activated by the use of methanol, 
water and phosphoric acid. The samples (25ml) 
with the added phosphoric acid were missed 
through the activated columns. The columns 
were rinsed with phosphoric acid and ammonium 
acetate and dried under vacuum. After rinsing 
and drying columns, the investigated substances 
were eluted with methanol. The methanol 
solution was matched to dry and dissolved in a 
solution of mobile phase to volume of 250µL. 
 
Table 1.  Chemical structure of investigated substances 
 



































The separations were performed on Hewlett 
Packard 1100 HPLC system with a spectro-
photometry detection and chromatographic colimn 
Zorbax Eclipse RP - 8, 5µm, 150 • 4,6mm. The 
determination of fosinopril and fosinoprilat were 
performed with methanol 66% (v/v), water 34% 
(v/v), triethanolamine 0.1% (v/v) and pH 5.5 
(acetate buffer) while cilazapril and cilazaprilat 
were determinated with methanol 41% (v/v), 
water 59% (v/v), triethanolamine 0.1% (v/v) at 
pH 2.3 (fosforic acid). The mobile phase was 
filtered through a 0.45 µm membrane filter. The 
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injection volume was 100 µL, flow rate was 1.0 
mL/min. The column was maintained at 25ºC. 
The chromatograms were recorded at 210 nm 
using DAD. Under these conditions the retention 
time for investigated substances was: cilazapril 
30 min., cilazaprilat 9 min., fosinopril 90 min. 
and fosinoprilat 10 min. 
The methanol of HPLC grade were Merck 
(Darmstadt,Germany). The deionized water was 
purified by Simplicity 185 system (Millipore, 
Billerica, MA). All other chemicals were of analytical 




Solutions for calibration curves were made 
by spiking blank dialisate samples with known 
amounts of examined substances and extracting 
them in the same way as unknown samples. The 
seven solutions of different concentrations for 
each calibration curve were prepared. The 
concentration range of calibration solutions were 




The elimination of ACE ihibitors with 
different hydrophobicity, fosinopril and cilazapril, 
and their active metabolites fosinoprilat and 
cilazaprilat, by dialysate in patients on peritoneal 
dialysis was examined by the use of HPLC method. 
Calibration graph was established by ploting 
average area of peak with drug concentration in 
prepared solutiones. The obtained calibration 
curves parameters are for cilazaprilat: Y = 19.3259 
X – 2.9756; R = 0.9883 and for fosinoprilat: Y = 
37.8883 X – 5.0457; R= 0.9967. 
The chromatograms of blank dialysate, 
blank dialysate spiked with examined ACE 
inhibitors and their metabolites, as well as the 
chromatograms of a dialysate samples obtained 
from patients after intake of fosinopril 20 mg or 
cilazapril 10 mg and after extraction procedure 




Figure 1. Chromatograms of  blank dialisate sample 
 
 
Figure 2. Chromatograms of  blank dialisate spiked with 
cilazapril and cilazaprilat (A), blank dialisate spiked with 
fosinopril and fosinoprilat (B) 
 
 
Figure 3.  Chromatograms of dialisate sample obtained 
from patient after intake of cilazapril 10 mg (A) and 
fosinopril 20 mg (B) 
 
The samples of peritoneal dialysate contained 
only metabolites of examined ACE inhibitors, 
consistent to fast in vivo hydrolysis of ACE 
inhibitors. The results are presented in Table 2. 
Both studied metabolites are eliminated via 
the dialysate in a very low percentage: 0.4153% 
of administered fosinopril in the form of its 
metabolite fosinoprilat, and 0.6557% of admini-
stered cilazapril in the forms of cilazaprilat. 
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Table 2. The elimination of fosinoprilat and cilazaprilat 
by dialisate at hypertensive patients 12h after intake of 














1.* 2000 82,9 0,4145 
2. * 2080 79,4 0,3968 
3. * 2010 84,1 0,4203 
4. * 1980 84,4 0,4220 
5. * 2020 83,5 0,4175 
6. * 1990 80,4 0,4020 
7. * 2110 85,7 0,4285 
8. * 2050 84,3 0,4215 
9.** 1850 67,7 0,6766 
10.** 2050 63,5 0,6354 
11. ** 2030 65,4 0,6536 
12. ** 1970 64,3 0,6432 
13. ** 2120 66,1 0,6614 
14. ** 2090 65,9 0,6589 
15. ** 1990 65,8 0,6577 
16. ** 2000 65,9 0,6592 
*Patients who ingested 20mg of fosinopril  




Pharmacological properties of ACE inhibitors 
may be very different due to differences in chemical 
properties of their molecules.  
Resorption of ACE inhibitors from the 
gastrointestinal tract shows significant differences. 
Enalapril, cilazapril and quinapril are relatively 
well absorbed, by about 60%, fosinopril shows 
lower absorption (36%), while lisinopril shows 
the lowest one of about 25%, although it can 
range from 6-60% (8).  
Metabolites of ACE inhibitors are bound to 
plasma proteins. However, the degree of their 
binding is very different and vary from 0% for 
lisinopril to 98% for fosinoprilat and quinaprilat 
(8).  
ACE inhibitors and their metabolites are 
mostly eliminated by the urine. The exception is 
fosinoprilat that has a double (compensatory) 
way of elimination (urine as well as feces). This 
makes fosinopril especially suitable for patients 
with renal failure (8).  
The elimination of ACE inhibitors by dialysate 
is very different. The lisinopril has good elimination 
by dialysis, while the elimination cilazaprilat and 
fosinoprilat is minimal (8). The elimination of 
substances through the dialysate is a complex 
process influenced by many factors, such as 
molecular weight, molecules size, binding to 
plasma proteins, volume of distribution, water 
solubility (hydrophilicity or lipophilicity), plasma 
clearance. The molecules with higher molecular 
weight, lipophilicity and protein binding show 
lower elimination through the dialysate (9).  
In previous studies, there is little data on 
the elimination of ACE inhibitors by peritoneal 
dialysate (8,9). In this paper, the elimination of 
fosinopril, cilazapril and their metabolites by 
peritoneal dialisate in patients on peritoneal 
dialyse was studied. The results suggest that 
fosinopril and cilazapril are eliminated by 
dialysate in the form of their active metabolites 
fosinoprilat and cilazaprilat, and that the degree 
of their elimination is low. Slightly higher 
elimination of cilazaprilat compared to fosinoprilat is 
consistent with the fact that increase of drugs 
lipophilicity leads to decrease of its elimination by 
the dialysate. Another reason for fosinoprilat poor 
elimination can be the lower molecular weight of 
cilazaprilat (389.45), compared to fosinoprilat 
(434.49), as well as high degree of fosinopril 




Lipophilicity significantly affects the pharmaco-
kinetics and pharmacodynamics of drugs, their 
absorption, metabolism, distribution, activity and 
elimination. In this paper, the elimination of two 
ACE inhibitors - cilazapril and fosinopril, and their 
active metabolites - cilazaprilat and fosinoprilat 
was examined by the HPLC method. It was found 
that both ACE inhibitors are eliminated in the 
form of their metabolites in very small percent. 
Also, the obtained results show that the 
elimination of very lipophilic fosinoprilat by 
peritoneal dialysate is lower than the elimination 
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ELIMINACIJA INHIBITORA ANGIOTENZIN KONVERTUJUĆEG ENZIMA  
PUTEM PERITONEUMSKOG DIJALIZATA 
 
Jadranka Odović i Jasna Trbojević-Stanković 
 
 
 Inhibitori angiotenzin–konvertujućeg enzima (ACE inhibitori) najčešće su propisivani 
antihipertenzivni lekovi. Iako pripadaju istoj grupi lekova i pokazuju sličnu kliničku 
efikasnost, pojedini ACE inhibitori imaju različite farmakološke osobine, što može biti 
posledica njihovih različitih hemijskih karakteristika. Jedna od najznačajnijih osobina 
biološki aktivnih supstanci je njihova lipofilnost. Ona utiče na njihovu apsorpciju, 
raspodelu u tkiva, aktivnost, eliminaciju.  U ovom radu proučavana je eliminacija ACE 
inhibitora fosinoprila i cilazaprila dijalizatom kod bolesnika na peritoneumskoj dijalizi i 
uticaj lipofilnosti na ovaj put njihove eliminacije. Acta Medica Medianae 2011;50(2):12-
17. 
 
Ključne reči: Inhibitori angiotenzin–konvertujućeg enzima (ACE inhibitori), 
peritoneumska dijaliza, eliminacija, lipofilnost 
